Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study-Reference-Cited by-同舟云学术

Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

Published:2015-04-28 Issue:3 Volume:25 Page:466-477
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care (Engl)

Author:

Jönsson L.¹,Justo N.²,Musayev A.³,Krishna A.⁴,Burke T.⁵,Pellissier J.⁶,Judson I.⁷,Staddon A.⁸,Blay J.Y.⁹

Affiliation:

1. Department of Neurobiology, Care Sciences and Society; Karolinska Institut; Stockholm

2. Mapi Group; Stockholm Sweden

3. Medtronic; Tolochenaz Switzerland

4. Novartis Pharmaceuticals Corporation; Florham Park NJ USA

5. Global Health Outcomes, Oncology, Global Health Outcomes; Merck; Whitehouse Station NJ USA

6. Merck Research Laboratories; Merck & Co., Inc.; Upper Gwynedd PA USA

7. Royal Marsden Hospital; London UK

8. Abramson Cancer Center; Pennsylvania Hospital; Philadelphia PA 19106 USA

9. Centre Léon Bérard; University Claude Bernard Lyon I; Lyon Cedex France

Funder

Merck

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12322/fullpdf

Reference22 articles.

1. Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United Kingdom;Amdahl;Sarcoma,2014

2. A phase II study of ET-743/trabectedin (‘Yondelis’) for patients with advanced gastrointestinal stromal tumours;Blay;European Journal of Cancer,2004

3. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Casali;Annals of Oncology,2010

4. Chawla S. Blay J. Ray-Coquard I. Cesne A. Staddon A. Milhem M. Penel N. Riedel R. Nguyen B. Cranmer L 2011 Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)

5. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing;Ducimetiere;PLoS ONE,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare resource utilisation and costs in patients with advanced soft tissue sarcoma: A data linkage project using a sarcoma referral centre in Australia;2024-04-01

2. Direct Costs of Care for Adults with Soft Tissue Sarcomas: A Population-Based Study;Cancers;2022-06-24

3. Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective;Cost Effectiveness and Resource Allocation;2020-02-03

4. Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France;Sarcoma;2018-09-12

5. UK and Twenty Comparable Countries GDP-Expenditure-on-Health 1980-2013: The Historic and Continued Low Priority of UK Health-Related Expenditure;International Journal of Health Policy and Management;2016-07-10